Publications by authors named "Louise Knott"
Breast Cancer Res Treat
November 2020
Article Synopsis
- - The study investigates the effect of prior neoadjuvant/adjuvant trastuzumab (NAT) on the effectiveness of first-line HER2-targeted therapy (trastuzumab, pertuzumab, and taxane) in patients with HER2-positive metastatic breast cancer.
- - Findings indicate that patients who previously received NAT had a lower median progression-free survival (15.8 months) compared to those who did not (24.3 months), although overall survival rates were not significantly affected by prior NAT exposure.
- - De novo metastatic breast cancer patients showed the best outcomes, with longer median progression-free survival (25.2 months) and overall survival (91.2 months), highlighting the potential differences in treatment responses based
